EUVIMEDEUVIMED entdecken
Crossref

A comprehensive study on aberrant CD20+ mycosis fungoides: clinical and prognostic insights

Hatice Şanlı, İncilay Yıldızhan, Merve Alızada iD, Ahmet Taha Aydemir, Aylin Okçu Heper, Ayça Kırmızı, Bengu Nisa Akay iD

Clinical and Experimental Dermatology · 2024

DOI: 10.1093/ced/llae297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Hatice Şanlı und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Ankara University Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Mycosis Fungoides, Antigens, CD20, Skin Neoplasms. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As the majority of T-cell lymphomas lack CD20 expression, cases of mycosis fungoides (MF) exhibiting aberrant CD20 expression are exceedingly uncommon.

Objectives

To comprehensively evaluate the clinical, histopathological and prognostic features of seven patients diagnosed with CD20+ MF.

Methods

This retrospective study involved seven cases of MF with aberrant CD20 expression. The study provides details of demographics, clinical features, histopathology and treatment outcomes. Key timepoints include initial diagnosis of MF, detection of CD20 expression and follow-up, with a mean follow-up of 46 months.

Results

Aberrant CD20+ MF was diagnosed at an average age of 58.6 years, approximately 5.6 years after the first MF diagnosis. Following CD20 detection, patients presented with advanced disease stages, requiring treatments such as chemotherapy, brentuximab vedotin and allogeneic haematopoietic stem cell transplantation. Four patients died from lymphoma, with an average survival time of 52 months.

Conclusions

Aberrant CD20 expression in MF is rare but indicates a progressive course associated with poor prognosis. This often requires systemic chemotherapy and, in certain instances, allogeneic haematopoietic stem cell transplantation. This study provides important insights into the clinical attributes, disease progression and treatment options for patients with MF with aberrant CD20 expression. Further research is necessary to validate the effectiveness of emerging therapies and enhance our understanding of the underlying mechanisms and prognostic determinants specific to this unique MF subgroup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycosis FungoidesAntigens, CD20Skin NeoplasmsHumansMiddle AgedMaleRetrospective StudiesFemalePrognosisAgedAdultHematopoietic Stem Cell Transplantation

Substanzen

Antigens, CD20

Autor:innen und Institutionen

  • Department of Dermatology, Ankara University Faculty of Medicine, Ankara, Turkey.
  • Mamak State Hospital, Department of Dermatology, Ankara, Turkey.
  • Department of Pathology, Ankara University Faculty of Medicine, Ankara, Turkey.

ORCID-Profile: Merve Alızada, Bengu Nisa Akay

Zitieren

APA

Şanlı, H., Yıldızhan, İ., Alızada, M., Aydemir, A. T., Heper, A. O., Kırmızı, A., & Akay, B. N. (2024). A comprehensive study on aberrant CD20+ mycosis fungoides: clinical and prognostic insights. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae297

Vancouver

Şanlı H, Yıldızhan İ, Alızada M, Aydemir AT, Heper AO, Kırmızı A, et al. A comprehensive study on aberrant CD20+ mycosis fungoides: clinical and prognostic insights. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae297

BibTeX
@article{anl2024,
  author = {Şanlı, Hatice and Yıldızhan, İncilay and Alızada, Merve and Aydemir, Ahmet Taha and Heper, Aylin Okçu and Kırmızı, Ayça and Akay, Bengu Nisa},
  title = {A comprehensive study on aberrant CD20+ mycosis fungoides: clinical and prognostic insights},
  journal = {Clinical and Experimental Dermatology},
  year = {2024},
  doi = {10.1093/ced/llae297}
}
Kostenlos starten →